case_images: PMC10624194_01
case_images: Computed tomography (CT) of chest in different treatment phases. Lung and left pleura metastasis were found one year after radical surgery (A). Pleural effusion was appeared after combined therapy of gemcitabine and carboplatin and sintilimab (B). After paclitaxel albumin and doxorubicin hydrochloride liposome and sintilimab combined treatment for two and six months, pleural effusion was stable (C and D). Continued paclitaxel albumin and sintilimab combined treatment for another fifteen months, lesions were controlled well (E).
case_images: OTT-16-885-g0001.jpg
case_images: PMC10624194_01_OTT-16-885-g0001.jpg
case_images: f0001
case_images: However, in a follow-up in December 2019, Computed Tomography (CT) and Positron Emission Tomography (PET)-CT revealed lung and left pleura metastasis (Figures 1A and 2). Unfortunately, the patient developed disease progression with newly pleural effusion in February 2020 after two cycles of treatment (Figure 1B). Soon, the left pleural effusion was effectively controlled and PR (Figures 1C and 3) was obtained within six-cycles therapy (Figures 1D and 3). The patient received sintilimab and paclitaxel-albumin as maintenance therapy and showed progression in March 2022 (Figures 1E and 3).
case_images: Positron emission tomography (PET)-CT revealed lung and left pleura metastasis.
case_images: OTT-16-885-g0002.jpg
case_images: PMC10624194_01_OTT-16-885-g0002.jpg
case_images: f0002
case_images: However, in a follow-up in December 2019, Computed Tomography (CT) and Positron Emission Tomography (PET)-CT revealed lung and left pleura metastasis (Figures 1A and 2).
case_images: The timeline from diagnosis of metaplastic breast cancer to different stages of therapeutic regime and evaluation.
case_images: OTT-16-885-g0003.jpg
case_images: PMC10624194_01_OTT-16-885-g0003.jpg
case_images: f0003
case_images: Then, the regimen was changed to sintilimab (200mg, Q3W), and paclitaxel-albumin (260mg/m2, Q3W) plus doxorubicin hydrochloride liposome (20mg/m2, Q3W), started from March 2020 (Figure 3). Soon, the left pleural effusion was effectively controlled and PR (Figures 1C and 3) was obtained within six-cycles therapy (Figures 1D and 3). The patient received sintilimab and paclitaxel-albumin as maintenance therapy and showed progression in March 2022 (Figures 1E and 3). The tumor was controlled and SD was obtained with six cycles therapy (Figure 3). The patient received sintilimab and anlotinib as maintenance therapy and showed progression in January 2023 (Figure 3). Unfortunately, the patient died on June 2023 (Figure 3).
case_images: PMC10624194_02